well, it comes down to sizing. these pre-revenue biotechs are small relative to my other holdings, so i've sized them correctly. But in terms of missing the point - just so that i'm clear, you're saying that RNXT will tank before their 60% readout in 4 months?
Tell you what. Let's check back in 3 months - beginning of November. Let's see:
1. What the price of NVDA is relative to 128.6, where i went short.
2. If RNXT is still in business.
If either NVDA is higher, or RNXT has tanked, I will delete all of my accounts and never post again. But, if NVDA is down and RNXT is still kicking, you have to do the same. Up for the wager?
Tell you what. Let's check back in 3 months - beginning of November. Let's see:
1. What the price of NVDA is relative to 128.6, where i went short.
2. If RNXT is still in business.
If either NVDA is higher, or RNXT has tanked, I will delete all of my accounts and never post again. But, if NVDA is down and RNXT is still kicking, you have to do the same. Up for the wager?
Recent RNXT News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/16/2026 09:10:26 PM
- Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/09/2026 02:19:11 PM
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum • GlobeNewswire Inc. • 04/08/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:02 AM
- RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 • GlobeNewswire Inc. • 04/01/2026 06:20:16 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/31/2026 08:19:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:38:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:03 PM
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 11:00:10 AM
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment • GlobeNewswire Inc. • 03/26/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 01:16:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 01:16:41 AM
- RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement • GlobeNewswire Inc. • 03/23/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:38 AM
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET • GlobeNewswire Inc. • 03/20/2026 12:30:00 PM
- RenovoRx Announces $10 Million at Market Private Placement • GlobeNewswire Inc. • 03/18/2026 12:35:18 PM
- RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum • GlobeNewswire Inc. • 02/27/2026 01:30:00 PM
- RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting • GlobeNewswire Inc. • 02/26/2026 01:30:00 PM
- RenovoRx Establishes RenovoCath® Medical Advisory Board • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 12:00:43 PM
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer • GlobeNewswire Inc. • 02/05/2026 01:30:00 PM
